Latest News

Researchers, led by Thazin Nwe Aung, PhD, in the laboratory of David Rimm, MD, PhD, have developed a way to predict how lung cancer cells will respond to different therapies, allowing people with the most common form of lung cancer to receive more effective individualized treatment.

Later this week, at the 2025 ESMO Congress in Madrid, Spain, YCC researchers will deliver oral presentations, participate in panel discussions, and lead educational sessions covering a wide range of topics, including targeted therapies, biomarkers for resistance to immunotherapy, innovative combination therapies for advanced colorectal cancer, and advancements in patient supportive care.

The Rimm Lab at Yale Pathology, under the direction of David Rimm, MD, PhD, Anthony N. Brady Professor of Pathology and professor of medicine (medical oncology), marks 30 years of research, innovation, and training.

Yale Cancer Center faculty and trainees joined 22,000 cancer researchers from around the world to share the latest advances in cancer science and medicine earlier this week in Chicago for the 116th American Association for Cancer Research (AACR) annual meeting. Dr. Patricia LoRusso, Amy and Joseph Perella Professor of Medicine at Yale Cancer Center and AACR President for 2024-25, shared her global view on cancer. “Cancer is a global disease—it spares no continent, no country. And each patient that gets the disease deserves treatment.”

Yale Cancer Center presentations at the AACR Annual Meeting will include oral and poster presentations as well as educational sessions, showcasing cutting-edge cancer science and medicine.

Tumour-infiltrating lymphocytes (TILs) are crucial effectors of the anticancer immune response and are hypothesized to be key determinants the efficacy of immune-checkpoint inhibitors (ICIs). Herein, the authors review studies that have evaluated the roles of various TIL subsets as predictive biomarkers for ICIs, as well as opportunities, challenges and strategies for future research in this field.

Chen Liu, MD, PhD, Chair of Yale Pathology, welcomes public school students to the 2nd Annual Yale Pathology Day, where they explored careers in pathology.

More than half of human cancers, called “non-inflamed” or “cold” tumors, are not being effectively infiltrated by the cancer-fighting T cells. Essentially, the soldiers are excluded from the battlefield. Yale Cancer Center researchers want to know why.

The Yale Advanced Diagnostic Tests Laboratory in the Department of Pathology, a new unit of Yale Pathology Laboratories, offers access to novel molecular tests to external users, performing and interpreting clinical grade and high-quality molecular analysis of human tissue samples.